摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-iodo-5-carboxy-9(10H)-acridanone | 86611-62-3

中文名称
——
中文别名
——
英文名称
3-iodo-5-carboxy-9(10H)-acridanone
英文别名
9,10-dihydro-6-iodo-9-oxoacridine-4-carboxylic acid;6-Iodo-9-oxo-9,10-dihydroacridine-4-carboxylic acid;6-iodo-9-oxo-10H-acridine-4-carboxylic acid
3-iodo-5-carboxy-9(10H)-acridanone化学式
CAS
86611-62-3
化学式
C14H8INO3
mdl
——
分子量
365.127
InChiKey
UPVSWPJPWVOUAE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    529.0±50.0 °C(Predicted)
  • 密度:
    1.889±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    66.4
  • 氢给体数:
    2
  • 氢受体数:
    4

SDS

SDS:48bb8d0b275e9ad8178f3463ffcd8369
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS
    申请人:Madelmont Jean-Claude
    公开号:US20100061928A1
    公开(公告)日:2010-03-11
    The present invention relates to the use of a compound of formula (I): in which R 1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R 2 and R 3 represent, independently of one another, a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkenyl group or an aryl group chosen from a phenyl, benzyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, furyl and thienyl group, and their addition salts with pharmaceutically acceptable acids, in the preparation of a radiopharmaceutical composition intended for the diagnosis and/or treatment of melanoma.
    本发明涉及使用式(I)化合物:其中R1代表放射性核素,Ar代表芳香环,m为2到4的整数,R2和R3代表独立的氢原子,(C1-C6)烷基,(C1-C6)烯基或苯基,所述苯基选择自苯基,苄基,咪唑基,吡啶基,嘧啶基,吡嗪基,吲哚基,吲唑基,呋喃基和噻吩基,并且它们与药学上可接受的酸的加成盐,用于制备放射性药物组合物,用于诊断和/或治疗黑色素瘤。
  • Labelled analogues of halobenzamides as radiopharmaceuticals
    申请人:INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    公开号:EP2363399A1
    公开(公告)日:2011-09-07
    The present invention relates to the use of a compound of formula (I): in which R1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R2 and R3 represent, independently of one another, a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or an aryl group chosen from a phenyl, benzyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, furyl and thienyl group, and their addition salts with pharmaceutically acceptable acids, in the preparation of a radiopharmaceutical composition intended for the diagnosis and/or treatment of melanoma.
    本发明涉及式(I)化合物的用途: 其中 R1 代表放射性核素 Ar 代表芳香核 m 是 2 至 4 之间的整数、 R2和R3相互独立地代表氢原子、(C1-C6)烷基、(C1-C6)烯基或选自苯基、苄基、咪唑基、吡啶基、嘧啶基、吡嗪基、吲哚基、吲唑基、呋喃基和噻吩基的芳基,以及它们与药学上可接受的酸的加成盐,用于制备诊断和/或治疗黑色素瘤的放射性药物组合物。
  • Potential antitumor agents. Part 38. 3-Substituted 5-carboxamido derivatives of amsacrine
    作者:William A. Denny、Graham J. Atwell、Bruce C. Baguley
    DOI:10.1021/jm00365a013
    日期:1983.11
    The synthesis and biological evaluation of a series of 3-substituted 5-carboxamido derivatives of amsacrine (m-AMSA) are described. This series was developed as the result of previous quantitative structure-activity relationship (QSAR) studies of the antitumor activity of 9-anilinoacridine derivatives. In agreement with these studies, this class of compounds, possessing a variety of small nonpolar groups at the 3-position, together with very hydrophilic carboxamido groups at the 5-position, have high in vivo activity against animal leukemia models.
  • [EN] LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS<br/>[FR] ANALOGUES MARQUÉS D'HALOBENZAMIDES UTILISÉS COMME PRODUITS RADIOPHARMACEUTIQUES
    申请人:INST NAT SANTE RECH MED
    公开号:WO2008012782A3
    公开(公告)日:2008-06-05
  • STEWART, G. M.;REWCASTLE, G. W.;DENNY, W. A., AUSTRAL. J. CHEM., 1984, 37, N 9, 1939-1950
    作者:STEWART, G. M.、REWCASTLE, G. W.、DENNY, W. A.
    DOI:——
    日期:——
查看更多